Find clinical trials for Colon Cancer in Montréal, QC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Colon Cancer trials near Montréal, QC, CAN:
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Montreal, Canada and 250 other locations
and pembrolizumab) given together for the treatment of colorectal cancer that:* is metastatic (spread to other parts of the body);* has the ...
Phase 2
Montreal, Quebec, Canada and 111 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
Montreal, Quebec, Canada and 878 other locations
Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET...
Phase 2
Montreal, Quebec, Canada and 90 other locations
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab ver...
Phase 3
Montreal, Quebec, Canada and 282 other locations
with standard chemotherapy for the potential treatment of colorectal cancer that:* has spread to other parts of the body (metastatic);* has ...
Phase 3
Montreal, Quebec, Canada and 410 other locations
is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer...
Phase 1, Phase 2
Montréal, Quebec, Canada and 46 other locations
Endoscopic Mucosal Resection (EMR) is the current standard for effective endoscopic resection of such colon adenomas. If resection is possib...
Montréal, Quebec, Canada
Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxa...
Phase 2
Montreal, Quebec, Canada
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Montréal, Quebec, Canada and 65 other locations
Clinical trials
Research sites
Resources
Legal